Teva Pharmaceutical Industries (TEVA) Share-based Compensation: 2009-2025
Historic Share-based Compensation for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $34.0 million.
- Teva Pharmaceutical Industries' Share-based Compensation rose 17.24% to $34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.0 million, marking a year-over-year increase of 19.66%. This contributed to the annual value of $123.0 million for FY2024, which is 1.65% up from last year.
- As of Q3 2025, Teva Pharmaceutical Industries' Share-based Compensation stood at $34.0 million, which was down 10.53% from $38.0 million recorded in Q2 2025.
- Teva Pharmaceutical Industries' Share-based Compensation's 5-year high stood at $39.0 million during Q2 2022, with a 5-year trough of $24.0 million in Q1 2022.
- Over the past 3 years, Teva Pharmaceutical Industries' median Share-based Compensation value was $32.0 million (recorded in 2024), while the average stood at $31.8 million.
- Per our database at Business Quant, Teva Pharmaceutical Industries' Share-based Compensation skyrocketed by 34.48% in 2022 and then decreased by 23.08% in 2023.
- Teva Pharmaceutical Industries' Share-based Compensation (Quarterly) stood at $33.0 million in 2021, then increased by 9.09% to $36.0 million in 2022, then dropped by 22.22% to $28.0 million in 2023, then rose by 21.43% to $34.0 million in 2024, then climbed by 17.24% to $34.0 million in 2025.
- Its Share-based Compensation was $34.0 million in Q3 2025, compared to $38.0 million in Q2 2025 and $34.0 million in Q1 2025.